Biogen Inc., of Cambridge, Mass., said new data, that will be presented at the American Academy of Neurology (AAN) meeting in Washington, continue to support Tecfidera (dimethyl fumarate) as an effective, long-term treatment for people who are living with relapsing forms of multiple sclerosis (MS).